Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer

Phase 4

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Capecitabine

First Posted Date: 2015-10-21

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 63

Registration Number: NCT02581423

A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum

Phase 4

Completed

Conditions: Colorectal Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Bevacizumab
Drug: Irinotecan
Drug: Oxaliplatin

First Posted Date: 2015-10-21

Last Posted Date: 2017-03-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT02582970

A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Enfuvirtide

First Posted Date: 2015-10-21

Last Posted Date: 2016-07-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 23

Registration Number: NCT02582983

Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples

Completed

Conditions: Breast Cancer

First Posted Date: 2015-10-20

Last Posted Date: 2016-02-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 30

Registration Number: NCT02580799

Locations: 🇹🇷
Istanbul University Istanbul Medical Faculty, Istanbul, Turkey
🇹🇷
Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey
🇹🇷
Ankara University Medical Faculty, Ankara, Turkey

and more 2 locations

A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)

Phase 4

Completed

Conditions: Kidney Transplantation

Interventions: Biological: DT
Drug: Daclizumab
Biological: KLH

First Posted Date: 2015-10-15

Last Posted Date: 2016-01-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 11

Registration Number: NCT02576145

A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer

Phase 2

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Capecitabine
Drug: Peginterferon alfa-2a

First Posted Date: 2015-10-15

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 16

Registration Number: NCT02576964

A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous Administration

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PEG-IFN alfa-2a BA-free formulation (Test)
Drug: PEG-IFN alfa-2a market formulation (Reference)

First Posted Date: 2015-10-09

Last Posted Date: 2017-03-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 277

Registration Number: NCT02573025

Locations: 🇭🇰
The University of Hong Kong; Pharmacy Clinical Trials, Hong Kong, Hong Kong
🇳🇿
Christchurch Clinical Studies Trust, Christchurch, New Zealand
🇳🇿
Auckland Clinical Studies Limited, Grafton, New Zealand

and more 6 locations

Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo matched to prednisone
Drug: Prednisone
Biological: Tocilizumab

First Posted Date: 2015-10-09

Last Posted Date: 2019-11-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 314

Registration Number: NCT02573012

Locations: 🇫🇷
Hopital Pellegrin; Rhumatologie, Bordeaux, France
🇫🇷
Hopital Cochin; Rhumatologie B, Paris, France
🇫🇷
Hopital Hautepierre; Rhumatologie, Strasbourg, France

and more 36 locations

A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)

Phase 4

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: Peginterferon alfa-2a

First Posted Date: 2015-10-07

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT02570191

A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma

Phase 3

Completed

Conditions: Lymphoma, Follicular

Interventions: Drug: Rituximab

First Posted Date: 2015-10-07

Last Posted Date: 2015-12-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 124

Registration Number: NCT02569996

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy